Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Psoriasis
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Psoriasis

Warning

Psoriasis: A common, chronic, inflammatory skin disorder that is characterized by scaly plaques affecting scalp, elbows, knees and sacrum but in more severe forms can affect any part of the body. Incidence up to 2% of the UK population. Nail changes including pitting, onycholysis and sub-ungual hyperkeratosis may be seen in 50% and an inflammatory polyarthritis in up to 14%. Palmoplantar pustulosis (PPP) is characterized by crops of sterile pustules on the palms and soles that erupt repeatedly over months or years and is strongly associated with smoking. Guttate psoriasis consists of a widespread eruption of many small scaly plaques and often follows a streptococcal throat infection. Generalised pustular psoriasis with background erythema studded with small pustules is a rare but severe form of psoriasis that may be life threatening. Psoriasis is a systemic disorder associated with an increased risk of cardiovascular disease; always assess cardiovascular risk factors. 

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Treatment/ therapy

Mild: localised plaques with limited impact on quality of life usually managed with topical treatment 

Assess lifestyle factors that may precipitate or aggravate psoriasis i.e. smoking, alcohol, obesity, certain medications and infections. 

 

Emollients – prescribe to soften scale (use fingertip measurement) 

 

Vitamin D with Steroid combined: 

  • Ointment, Cream, Gel, Foam: Apply OD for 4 weeks, review and repeat as necessary 

Calcipotriol with Betamethasone preparations:  

Non-branded ointment  

Dovobet®, Dalonev®, Dalbecal® ointments Dovobet® gel  

Wynzora® cream 

Enstilar® foam  

Useful for plaques on body and limbs. Not suitable for face or flexures. 

 

Vitamin D preparations: 

 

  • Calcipotriol (non-branded) ointment and l scalp solution apply OD/BD 

Calcipotriol (Dovonex®)  ointment apply OD/BD 

Calcitriol (Silkis®)  ointment apply BD 

Tacalcitol (Curatoderm®) ointment or  lotion apply BD. 

NB: Calcitriol and Tacalcitol may be less irritating than Calcipotriol and may be more suitable for sensitive areas like face and genitals. 

 

Topical Corticoteroids: 

  • Mild: OD facial psoriasis 

Moderately potent: OD face and flexural areas 

Potent:  OD trunk/limbs, BD palms/soles 

 

Coal Tar Preparations: 

  • Cream-Psoriderm® apply OD/BD 
  • Lotion-Exorex® apply OD/BD 
  • Shampoos: - Neutrogena T-Gel®, , Psoriderm® 

Polytar®, Capasal® (with salicylic acid), use up to OD 

 

Coal Tar + Salicylic acid and Sulfur:  

  • For scalp psoriasis mainly  

Cocois® ointment 100G apply up to OD 

Sebco® ointment 100G apply up to OD

Moderate psoriasis: Localised site or more widespread psoriasis > 10% body area 

Scalp psoriasis:  

  • Prescribe a regimen of coconut, tar and salicylic ointment (Sebco/Cocois) applied OD for an hour or overnight and wash off with tar-based shampoo to soften and remove thick scale. Reduce frequency as improves. 
  • Apply potent or very potent topical corticosteroid scalp solution / gel / foam (e.g. betamethasone +/- salicylic acid, clobetasol) OD after shampooing or, Vitamin D preparation, gel / foam OD, or corticosteroid + vitamin D (e.g. Dovobet® gel). 

 

Facial/Flexural psoriasis: 

  • Steroids: mild/moderate potency topical corticosteroid OD 

Vitamin D preparations: Calcitriol / Tacalcitol OD/BD may be used as less irritant than Calcipotriol 

Calcineurin inhibitors (e.g Protopic®) may be helpful but should be initiated by specialist. 

 

Nail psoriasis:  

  • Treatment difficult, keep trimmed, potent topical corticosteroid or Calcipotriol with Betamethasone combination OD may help 

 

PalmoPlantar Pustulosis: 

  • Associated with smoking.  

Steroids, potent or very potent topical corticosteroids OD/BD 

Calcipotriol with Betamethasone combination ointment OD 

 

Guttate Psoriasis: 

  • Widespread small plaques, self-limiting, often triggered 7-10 days after streptococcal URTI.  

Will often resolve spontaneously in weeks to months, useful treatments include: 

Mildly potent topical corticosteroid OD 

Vitamin D preparations OD 

Coal tar preparations OD 

 

  • Refer to secondary care for consideration of phototherapy and/or first line systemic therapy with Methotrexate, Ciclosporin or Acitretin for moderate to severe psoriasis failing to respond to treatment. 

 

Treatment failures with phototherapy and first line systemic therapies may require novel systemic therapy with phosphodiesterase type-4 inhibitor (Apremilast) or biologic therapies. 

Severe psoriasis: Widespread inflamed psoriasis or severe localised recalcitrant psoriasis (e.g. palms and soles) or affecting high impact sites like face or groin. 

Refer same day to dermatology/ emergency care for erythrodermic or generalised pustular psoriasis 

 

Refer to rheumatology if any evidence of psoriatic arthropathy. 

Referral Management

Mild: localised plaques with limited impact on quality of life usually managed with topical treatment 

  • Manage in primary care.  

Moderate psoriasis: Localised site or more widespread psoriasis > 10% body area 

  • Refer routinely to secondary care service if failure of appropriate topical treatment after 4 weeks  

Severe psoriasis: Widespread inflamed psoriasis or severe localised recalcitrant psoriasis (e.g. palms and soles) or affecting high impact sites like face or groin.

  • Consider referring urgently if psoriasis is very widespread and inflamed 
  • Emergency referral is indicated for erythrodermic or generalised pustular psoriasis. 
  • Refer to rheumatology if any evidence of psoriatic arthropathy. 

Clinical resources

Validated tools used to evaluate psoriasis include: 

DLQI 

PASI 

Skin Diversity descriptors 

Physician’s Global assessment tool 

Cardiovascular assessment  

Psoriatic Arthritis screening tool- PEST 

NICE CKS- Psoriasis 

PCDS- Psoriasis 

DermNet NZ- Psoriasis 

Clinical tips

  • Patient preference for type of topical preparation should guide effective treatment 
  • Psoriasis is a systemic disorder associated with an increased risk of cardiovascular disease; always assess cardiovascular risk factors. 
  • Excess alcohol, smoking and obesity can make psoriasis more difficult to control. 
  • Screen for arthritis and refer to rheumatology as needed. 

ICD search category(s)

Inflammatory 

ICD11 code - EA90.0          EA90.1

Editorial Information

Last reviewed: 23/05/2023

Next review date: 23/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society